Long-Term Effectiveness of a Digital Therapeutic Intervention for Smoking Cessation: A Randomized Controlled Trial

Background Smoking is the leading cause of preventable mortality worldwide. Digital therapeutic interventions offer a novel approach to smoking cessation and overcome many barriers to accessibility of traditional methods. Yet, the long-term efficacy of these interventions is largely unknown. Based on a chronic disease model of smoking, the present study evaluated the effects of Quit Genius, a novel, long-term digital therapeutic intervention for smoking cessation.

Methods and Findings Using a single-blind, two-arm parallel-group, randomized controlled trial design, adult smokers of 5 or more cigarettes per day (N=556) were recruited between January and November of 2019 via social media advertisements and referrals from primary care practices in the UK. Participants were offered nicotine replacement therapy for a 12-week period and randomly assigned to one of two interventions.The Quit Genius group received a digital therapeutic intervention for smoking cessation comprising a clinician supported smartphone application delivering cognitive behavioral therapy (CBT). The CBT component included self-directed coping skills training and individually tailored therapeutic content, coupled with personalized clinician-delivered counselling via instant messaging. The control intervention was Very Brief Advice, a face-to-face, single session intervention based upon the Ask, Advise, Act model. Half of each group received a carbon monoxide (CO) device for biochemical verification of smoking abstinence. The primary outcome, by intention to treat (ITT), was sustained abstinence at 4, 26, and 52 weeks post-quit date. Secondary outcomes included self-reported 7-day point prevalence abstinence at 26 and 52 weeks post-quit date, and self-reported quit attempts and putative mechanisms of action of CBT for smoking cessation, including self-efficacy and psychological well-being. Participants (N=556) were randomly assigned to Quit Genius (n=277) or the Very Brief Advice control condition (n=279).

The final sample included 530 participants, comprising roughly equivalent proportions of men (n=291; 54%) and women, averaging 41 years of age (SD=12), who smoked an average of 15 cigarettes per day (SD=7). Using an Intention-to-treat (ITT) analysis, seven-day point prevalence abstinence from weeks 4 through 52 ranged from approximately 27% to nearly 45% among those who received the Quit Genius intervention, and from 13% to 29% for those in the control condition. Continuous smoking abstinence at 26 and 52 weeks occurred in 27.2% and 22.6% of Quit Genius participants, respectively, relative to 16.6% and 13.2% of those assigned to the control group; Quit Genius participants were more likely to remain abstinent than those in the control group Relative Risk [RR]= 1.71, 95% CI 1.17-2.50; p=0.005).

Conclusions Using an extended care model combining NRT with evidence-based psychosocial treatment, a digital therapeutic intervention (Quit Genius) produces continuous abstinence rates that are notably higher than those typically observed in the literature.

Trial Registration The trial was registered in the ISRCTN database on December 18, 2018 (https://www.isrctn.com/ISRCTN65853476).